Biodesix Inc (BDSX): Koefisien rega marang pendapatan

Stable income from insurance payouts supports margins, which is reflected in the price/sales multiple dynamics of Biodesix, Inc. (BDSX). Growth is driven by rapid blood tests as an alternative to biopsies, while AI-powered robotics accelerate DNA sequencing. 1.00 represents the current value of the indicator, allowing for the visualization of business valuation deviations from revenue and the effective protection of capital against market drawdowns.

Biodesix (BDSX): Rasio rega marang pendapatan saka 04.07.2022 nganti 13.11.2026

Rincian analitis perusahaan Biodesix Corp (BDSX)

- kuotasi saiki lan rata-rata prakiraan nilai:

Rega bursa biodesix.com|BDSX - Bagan rega target

- data kapitalisasi bursa:

Kapitalisasi pasar Biodesix Corp|BDSX - Nilai Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Saham Biodesix|BDSX - Nilai Buku Perusahaan|Kapitalisasi Pasar marang Nilai Buku biodesix.com|BDSX - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

- data bathi resik lan rasio valuasi:

BDSX - Bathi resik perusahaan|Prakiraan bathi perusahaan Biodesix, Inc.|BDSX - Pangali P/E|Kapitalisasi marang proyeksi bathi Biodesix Inc|BDSX - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Biodesix Corp|BDSX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Biodesix|BDSX - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan biodesix.com|BDSX - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Biodesix, Inc.

- data total pendapatan lan volume dodolan:

BDSX - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan biodesix.com|BDSX - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Biodesix Corp

Analisis fundamental perusahaan:BDSX - biodesix.com

The P/S ratio determines the market value of a business relative to its annual sales volume, measuring the premium the market is willing to pay per unit of revenue. For Biodesix, Inc. (BDSX), a leader in AI-driven lung cancer diagnostics, this metric reflects the capitalization of its scientific and technical potential. By analyzing the company's revenue valuation, an investor can observe the demand dynamics for precision biopsy. Sharp fluctuations in the line indicate a shift in expectations regarding the pace of innovation commercialization.

Perusahaan pesaing